JP2013508408A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508408A5
JP2013508408A5 JP2012535413A JP2012535413A JP2013508408A5 JP 2013508408 A5 JP2013508408 A5 JP 2013508408A5 JP 2012535413 A JP2012535413 A JP 2012535413A JP 2012535413 A JP2012535413 A JP 2012535413A JP 2013508408 A5 JP2013508408 A5 JP 2013508408A5
Authority
JP
Japan
Prior art keywords
use according
cells
subject
cxcr
catheter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535413A
Other languages
English (en)
Japanese (ja)
Other versions
JP5709880B2 (ja
JP2013508408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053744 external-priority patent/WO2011050266A1/en
Publication of JP2013508408A publication Critical patent/JP2013508408A/ja
Publication of JP2013508408A5 publication Critical patent/JP2013508408A5/ja
Application granted granted Critical
Publication of JP5709880B2 publication Critical patent/JP5709880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012535413A 2009-10-23 2010-10-22 血管の機能不全による進行性心筋傷害治療のための組成物および方法 Expired - Fee Related JP5709880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25453909P 2009-10-23 2009-10-23
US61/254,539 2009-10-23
PCT/US2010/053744 WO2011050266A1 (en) 2009-10-23 2010-10-22 Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013236030A Division JP2014037433A (ja) 2009-10-23 2013-11-14 血管の機能不全による進行性心筋傷害治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013508408A JP2013508408A (ja) 2013-03-07
JP2013508408A5 true JP2013508408A5 (cg-RX-API-DMAC7.html) 2013-12-12
JP5709880B2 JP5709880B2 (ja) 2015-04-30

Family

ID=43900703

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012535413A Expired - Fee Related JP5709880B2 (ja) 2009-10-23 2010-10-22 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2013236030A Pending JP2014037433A (ja) 2009-10-23 2013-11-14 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2015219241A Expired - Fee Related JP6761236B2 (ja) 2009-10-23 2015-11-09 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2017222587A Pending JP2018043991A (ja) 2009-10-23 2017-11-20 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2020047382A Abandoned JP2020105216A (ja) 2009-10-23 2020-03-18 血管の機能不全による進行性心筋傷害治療のための組成物および方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013236030A Pending JP2014037433A (ja) 2009-10-23 2013-11-14 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2015219241A Expired - Fee Related JP6761236B2 (ja) 2009-10-23 2015-11-09 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2017222587A Pending JP2018043991A (ja) 2009-10-23 2017-11-20 血管の機能不全による進行性心筋傷害治療のための組成物および方法
JP2020047382A Abandoned JP2020105216A (ja) 2009-10-23 2020-03-18 血管の機能不全による進行性心筋傷害治療のための組成物および方法

Country Status (6)

Country Link
EP (2) EP3170891B1 (cg-RX-API-DMAC7.html)
JP (5) JP5709880B2 (cg-RX-API-DMAC7.html)
CA (1) CA2778664C (cg-RX-API-DMAC7.html)
ES (2) ES2610241T3 (cg-RX-API-DMAC7.html)
GB (1) GB2487339A (cg-RX-API-DMAC7.html)
WO (1) WO2011050266A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP5705127B2 (ja) * 2008-12-03 2015-04-22 アモーサイト インコーポレイテッド 梗塞領域灌流改善組成物および血管損傷修復の方法
CA2778664C (en) * 2009-10-23 2019-12-24 Amorcyte, Inc. Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US9533010B2 (en) 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2015073677A1 (en) * 2013-11-14 2015-05-21 The University Of Miami Non-expanded post-natal multilineage-inducible cells
US20150228115A1 (en) * 2014-02-10 2015-08-13 Kabushiki Kaisha Toshiba Medical-image processing apparatus and medical-image diagnostic apparatus
EP3247808B1 (en) 2015-01-21 2021-05-05 Fred Hutchinson Cancer Research Center Point-of-care and/or portable platform for gene therapy
CN109996535B (zh) * 2016-12-28 2024-02-23 日本乐敦制药株式会社 细胞药物组合物、疾病治疗用试剂盒和细胞悬浮用溶液
JP2021521193A (ja) * 2018-04-18 2021-08-26 スンマ ヘルスＳｕｍｍａ Ｈｅａｌｔｈ 虚血および心筋症の処置のための組成物および方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520110A (en) 1981-10-06 1985-05-28 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor
US5055556A (en) 1981-10-06 1991-10-08 The Board Of Trustees Of The Leland Stanford Jr. Univ. Fluorescent conjugates for analysis of molecules and cells
CA1179942A (en) 1981-10-06 1984-12-27 Lubert Stryer Fluorescent conjugates for analysis of molecules and cells
US4859582A (en) 1981-10-06 1989-08-22 The Board Of Trustees Of The Leland Stanford Jr. University Fluorescent conjugates for analysis of molecules and cells
US4965204A (en) 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5130144B1 (en) 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US5656493A (en) 1985-03-28 1997-08-12 The Perkin-Elmer Corporation System for automated performance of the polymerase chain reaction
US5333675C1 (en) 1986-02-25 2001-05-01 Perkin Elmer Corp Apparatus and method for performing automated amplification of nucleic acid sequences and assays using heating and cooling steps
FR2596413B1 (fr) 1986-03-27 1988-06-10 Merieux Inst Nouveaux milieux de culture de bacteries appartenant au genre bordetella, contenant des derives etherifies de polymeres de d-glucose, et leur application
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US5627027A (en) 1986-04-18 1997-05-06 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
US5569587A (en) 1986-04-18 1996-10-29 Carnegie Mellon University Method for labeling and detecting materials employing luminescent arysulfonate cyanine dyes
US4876190A (en) 1987-10-21 1989-10-24 Becton Dickinson & Company Peridinin-chlorophyll complex as fluorescent label
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5723218A (en) 1990-04-16 1998-03-03 Molecular Probes, Inc. Dipyrrometheneboron difluoride labeled flourescent microparticles
US5234824A (en) 1990-11-13 1993-08-10 Specialty Laboratories, Inc. Rapid purification of DNA
US5187083A (en) 1990-11-13 1993-02-16 Specialty Laboratories, Inc. Rapid purification of DNA
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5776709A (en) 1991-08-28 1998-07-07 Becton Dickinson And Company Method for preparation and analysis of leukocytes in whole blood
US5415636A (en) 1994-04-13 1995-05-16 Schneider (Usa) Inc Dilation-drug delivery catheter
US5968753A (en) 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US5980887A (en) 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US8075880B2 (en) 1999-01-11 2011-12-13 Steward St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for regulating angiogenesis
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
US6676937B1 (en) 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US7160935B2 (en) * 2003-04-04 2007-01-09 E. I. Du Pont De Nemours And Company Tubular reactor ethylene/alkyl acrylate copolymer as polymeric modifiers for asphalt
WO2006060779A2 (en) * 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
MY147516A (en) * 2005-11-07 2012-12-31 Amorcyte Inc Compositions and method of vascular injury repair cross-reference to related applications
EP2471903B1 (en) * 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
US20070190127A1 (en) * 2005-12-30 2007-08-16 Mingdong Zhou Extended release of neuregulin for improved cardiac function
JP5705127B2 (ja) * 2008-12-03 2015-04-22 アモーサイト インコーポレイテッド 梗塞領域灌流改善組成物および血管損傷修復の方法
CA2778664C (en) * 2009-10-23 2019-12-24 Amorcyte, Inc. Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
WO2018049376A1 (en) 2016-09-12 2018-03-15 Cornell University Computational systems and methods for improving the accuracy of drug toxicity predictions

Similar Documents

Publication Publication Date Title
JP2013508408A5 (cg-RX-API-DMAC7.html)
RU2497532C2 (ru) Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения
Gao et al. Therapeutic delivery of microRNA-125a-5p oligonucleotides improves recovery from myocardial ischemia/reperfusion injury in mice and swine
Moskalik et al. Multiple roles of cardiac macrophages in heart homeostasis and failure
JP2012510521A5 (cg-RX-API-DMAC7.html)
Lawall et al. Stem cell and progenitor cell therapy in peripheral artery disease
Walter et al. Endothelial progenitor cells: regulation and contribution to adult neovascularization
Brunner et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow‐derived progenitor cells via the CXCR‐4/SDF‐1 axis
Takahashi Role of the SDF-1/CXCR4 system in myocardial infarction
Ward et al. Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives
Li et al. Intravenous administration of atorvastatin-pretreated mesenchymal stem cells improves cardiac performance after acute myocardial infarction: role of CXCR4
Spadaccio et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study
Huang et al. SDF-1/CXCR4 mediates acute protection of cardiac function through myocardial STAT3 signaling following global ischemia/reperfusion injury
Hiasa et al. Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor
US12048687B2 (en) Methods of recruiting SDF-producing macrophages
Sanganalmath et al. Hematopoietic cytokines for cardiac repair: mobilization of bone marrow cells and beyond
Hristov et al. Adult progenitor cells in vascular remodeling during atherosclerosis.
IL232997A (en) Sterile Pharmacist's Composition for Vascular Injury Caused by Vascular Failure Containing Stem Cell Product
ES2845691T3 (es) Composiciones y usos para el tratamiento de lesiones miocárdicas progresivas debidas a una insuficiencia vascular
US8425899B2 (en) Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
Tian et al. Combined therapy with atorvastatin and atorvastatin-pretreated mesenchymal stem cells enhances cardiac performance after acute myocardial infarction by activating SDF-1/CXCR4 axis
KR101192136B1 (ko) 혈액 줄기 세포의 동원에 유효한 ｇ-ｃｓｆ와 ｐｌｇｆ의조합 약제
Brunner et al. Stem cell mobilisation for myocardial repair
Hristov et al. Ambivalence of progenitor cells in vascular repair and plaque stability
Li et al. Enhanced human adipose‐derived stem cells with VEGFA and bFGF mRNA promote stable vascular regeneration and improve cardiac function following myocardial infarction